Morningstar - Nektar Therapeutics (NKTR) Business as Usual for Nektar as It Continues Development of NKTR-214; Shares Fairly Valued

Report

Morningstar

Karen Andersen

EUR 100.00 For Business Accounts Only

Business as Usual for Nektar as It Continues Development of NKTR-214; Shares Fairly Valued

Nektar reported fourth-quarter results in line with our expectations, with nearly $40 million in revenue and a net loss of about $98 million. Research and development costs were about $109 million as the company funds several ongoing clinical development projects, most of which include the company's leading immuno-oncology candidate NKTR-214, now termed bempegaldesleukin or bempeg.
Management's guidance for 2019 included $100 million-$110 million in revenue, below our expectations, and operating...

01/03/2019 14 EN

Underlying

Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company. The company's proprietary drugs and drug candidates that have either received regulatory approval or are being developed by the company or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD?, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology.

See profile

US6402681083 NASDAQ Stock Market United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Karen Andersen

Other Reports on these Companies

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc 11-Oct-2022 / 14:01 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interes...

October 11, 2022 October 11, 2022 1 EN

EQS Group AG

Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc 10-Oct-2022 / 14:21 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interes...

October 10, 2022 October 10, 2022 1 EN

TheScreener

NEKTAR THERAPEUTICS suffers a double requalification, which weighs heavily on its rating, now at Negative.

The independent financial analyst theScreener just downgraded the general evaluation of NEKTAR THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date March 15, 2022, the closing price was USD 4.48 and its target price was estimated at USD 4.26.

Free Trial

March 16, 2022 March 16, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Business as Usual for Nektar as It Continues Development of NKTR-214; Shares Fairly Valued

Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc

Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc

NEKTAR THERAPEUTICS suffers a double requalification, which weighs heavily on its rating, now at Negative.

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe